We evaluated the cardiopulmonary exercise test results before and after long-term (16 weeks) treatment with the dihydropyridine calcium antagonist, felodipine (10 mg b.i.d., n = 9), and the ACE inhibitor, enalapril (10 mg b.i.d., n = 11), in 20 patients with New York Heart Association class III congestive heart failure. There were no significant differences at baseline. After 16 weeks patients in the enalapril group showed a significant increase in exercise duration and VO2max, without changes in arterial pressures and heart rate. In the felodipine group, exercise duration and VO2max did not change significantly, but arterial pressures and heart rate were significantly reduced at all exercise levels. Between group analysis showed a signific...
Hemodynamic effects of the new oral angiotensin-con-verting enzyme inhibitor, enalapril, were evalua...
Converting enzyme inhibition of the renin-angiotensin system has proved a valuable therapeutic appro...
AbstractPatients with New York Heart Association functional class II or III heart failure stabilized...
We evaluated the cardiopulmonary exercise test results before and after long-term (16 weeks) treatme...
Angiotensin-converting enzyme (ACE) inhibition is currently the cornerstone of congestive heart fail...
Felodipine (FEL) is a vasoselective dihydropyridine calcium antagonist that has shown promising resu...
Enalapril is a recently developed angiotensin-converting enzyme inhibitor that improves cardiac func...
This study was conducted to determine the effects of short-term enalapril treatment on left ventricu...
AbstractForty-one men with documented myocardial infarction > 6 months previously were randomized to...
Several studies have shown symptomatic and haemodynamic improvement after the introduction of angiot...
We performed a randomized double-blind placebo controlled cross-over study of enalapril in 16 patien...
Angiotensin-Converting enzyme inhibitors are effective vasodilators in the treatment of congestive h...
In 13 patients with congestive heart failure we tested the acute hemodynamic effects of 5 vs. 10 mg ...
The effect of lisinopril 5-20 mg once daily or enalapril 5-20 mg once daily on exercise capacity, ve...
Whereas ACE inhibition acutely reduces myocardial ischemia (MI) through neuroendocrine modulation an...
Hemodynamic effects of the new oral angiotensin-con-verting enzyme inhibitor, enalapril, were evalua...
Converting enzyme inhibition of the renin-angiotensin system has proved a valuable therapeutic appro...
AbstractPatients with New York Heart Association functional class II or III heart failure stabilized...
We evaluated the cardiopulmonary exercise test results before and after long-term (16 weeks) treatme...
Angiotensin-converting enzyme (ACE) inhibition is currently the cornerstone of congestive heart fail...
Felodipine (FEL) is a vasoselective dihydropyridine calcium antagonist that has shown promising resu...
Enalapril is a recently developed angiotensin-converting enzyme inhibitor that improves cardiac func...
This study was conducted to determine the effects of short-term enalapril treatment on left ventricu...
AbstractForty-one men with documented myocardial infarction > 6 months previously were randomized to...
Several studies have shown symptomatic and haemodynamic improvement after the introduction of angiot...
We performed a randomized double-blind placebo controlled cross-over study of enalapril in 16 patien...
Angiotensin-Converting enzyme inhibitors are effective vasodilators in the treatment of congestive h...
In 13 patients with congestive heart failure we tested the acute hemodynamic effects of 5 vs. 10 mg ...
The effect of lisinopril 5-20 mg once daily or enalapril 5-20 mg once daily on exercise capacity, ve...
Whereas ACE inhibition acutely reduces myocardial ischemia (MI) through neuroendocrine modulation an...
Hemodynamic effects of the new oral angiotensin-con-verting enzyme inhibitor, enalapril, were evalua...
Converting enzyme inhibition of the renin-angiotensin system has proved a valuable therapeutic appro...
AbstractPatients with New York Heart Association functional class II or III heart failure stabilized...